Is ubrogepant (Ubrelvy) appropriate as an acute rescue medication for a patient with near‑daily migraine attacks and a history of an old cerebral infarct?

Ubrelvy (Ubrogepant) for Near-Daily Migraine with Old Cerebral Infarct

Ubrelvy is appropriate as an acute rescue medication for this patient, but with critical limitations: it should not be used more than 8 migraine days per month, and you must simultaneously initiate preventive therapy to reduce attack frequency. 1

Key Clinical Considerations

Medication Overuse Risk - The Primary Concern

Your patient's near-daily migraine pattern creates immediate risk for medication overuse headache (MOH). The FDA label explicitly states: "It is not known if it is safe to take UBRELVY for more than 8 migraine headaches in 30 days." 1 This is not a guideline—it's a hard safety boundary from the drug label.

• MOH threshold for gepants: Using acute medications ≥10 days/month for triptans or ≥15 days/month for NSAIDs triggers MOH 2
• While gepant-specific MOH thresholds aren't established, the 8-attack-per-month limit suggests similar concerns
• Your patient needs preventive therapy immediately—this is non-negotiable with near-daily attacks 2

Cardiovascular Safety Profile

The old cerebral infarct raises legitimate vascular concerns, but ubrogepant has a favorable cardiovascular safety profile compared to triptans. A dedicated cardiovascular risk analysis from the ACHIEVE trials specifically evaluated patients with moderate-high CV risk factors and found:

• No increased treatment-emergent adverse events across CV risk categories 3
• No cardiac system organ class adverse events of concern 3
• Ubrogepant does not cause vasoconstriction (unlike triptans and ergots), making it mechanistically safer in patients with prior stroke 4

The FDA label does note potential for hypertension and Raynaud's phenomenon, but these are monitoring concerns, not contraindications 1.

Efficacy Data

Ubrogepant demonstrates solid acute efficacy:

• 21.8% achieve pain freedom at 2 hours (vs 14.3% placebo) 5
• 38.9% achieve freedom from most bothersome symptom at 2 hours (vs 27.4% placebo) 5
• Number needed to treat (NNT) = 12 for pain freedom, comparable to NSAIDs 4

Treatment Algorithm

Step 1: Initiate Preventive Therapy First

• Start a preventive medication immediately (topiramate, propranolol, or valproate per VA/DoD guidelines) 6
• Consider CGRP monoclonal antibodies or atogepant for chronic migraine prevention 6
• Goal: Reduce attack frequency to <8 days/month

Step 2: Use Ubrelvy as Breakthrough Rescue

• Dose: 50-100 mg at migraine onset 1
• Can repeat once after 2 hours if needed (maximum 200 mg/24 hours) 1
• Track usage meticulously—do not exceed 8 treated attacks per month 1

Step 3: Stepwise Acute Treatment Approach (per ACP 2025 guidelines) 2

• First-line: NSAID (naproxen 500-825 mg or ibuprofen 400-800 mg)
• Second-line: Add triptan to NSAID if inadequate response
• Third-line: Ubrelvy if triptan contraindicated (prior stroke) or inadequate response 2

Step 4: Monitor for Complications

• Blood pressure monitoring (hypertension risk) 1
• Watch for Raynaud's phenomenon (discontinue if occurs) 1
• Document headache frequency to prevent MOH

Critical Pitfalls to Avoid

1. Do not use Ubrelvy as monotherapy without preventive treatment in near-daily migraine—this violates both the FDA label and clinical guidelines
2. Do not use with strong CYP3A4 inhibitors (ketoconazole, clarithromycin, itraconazole)—absolute contraindication 1
3. Avoid grapefruit juice on days when second dose might be needed 1
4. Never use opioids or butalbital for this patient's migraine 2

Why Ubrelvy Over Triptans Here

The old cerebral infarct makes triptans relatively contraindicated due to their vasoconstrictive mechanism. While not an absolute contraindication in all cases, the 2025 ACP guidelines position gepants as alternatives for patients who "do not tolerate or have inadequate response" to triptans 2. A prior stroke reasonably falls into the "do not tolerate" category from a risk-benefit perspective.

Ubrelvy's CGRP receptor antagonism provides acute relief without vasoconstriction, making it mechanistically preferable in this vascular risk patient 4.

Bottom Line

Yes, prescribe Ubrelvy, but only as part of a comprehensive plan that includes preventive therapy. The near-daily pattern makes this patient inappropriate for acute-only treatment with any medication. Use Ubrelvy for breakthrough attacks while preventive therapy takes effect, strictly limiting to ≤8 attacks per month. The old infarct is not a contraindication—in fact, it makes Ubrelvy preferable to triptans—but the chronic migraine pattern demands preventive intervention regardless of which acute medication you choose.